First novel Schizophrenia treatment in decades gains FDA approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration ...
btimesonline2h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Medscape4h
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
FDA Approves Bristol Myers Squibb’s Schizophrenia Medication
The U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Bristol Myers Squibb’s (BMY) new schizophrenia drug called “Cobenfy.” The medication is the first new treatment for the ...
Zacks.com on MSN5h
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
Bristol Myers Squibb BMY announced that the FDA has approved xanomeline and trospium chloride (formerly KarXT), an oral ...
Why approval of KarXT, the first new drug for schizophrenia in decades, is a big deal
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
STAT5h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
The Financial Express6h
Bristol Myers gets USFDA nod for new type of schizophrenia drug
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.